Worldwide Clinical Trials | Oncology

Developing Next-Generation Therapies for Breast Cancer Patients

Breast cancer is a core area of expertise for Worldwide Clinical Trials. We support breast cancer programs from early-phase development through registrational studies across biomarker-defined patient populations and next-generation treatment modalities.

Successfully executing breast cancer trials requires expertise in biomarker-driven patient identification and enrollment, and molecular testing strategies across a highly competitive recruitment landscape. Partnering with an oncology CRO that understands these complexities is critical to accelerating development and study success.

Robust pipeline of breast cancer trials

Global Footprint

- Programs across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa

Study Experience

- 40+ breast cancer studies
- 4,300+ patients enrolled
- Early-phase through registrational development
- Support across HR+, HER2+, HER2-low, and other biomarker-defined patient populations

Site Experience

- 350+ unique sites
- Partner with leading academic centers and community oncology networks worldwide

Next-Generation Drug Modalities

- Antibody-drug conjugates (ADCs)
- Bispecific antibodies
- Cell therapy/CAR T
- Hormone antagonists
- Kinase inhibitors
- Cancer vaccines

We understand breast cancer trials

Disease Heterogeneity, Complex Sub-populations, and I/E Criteria

- ER+/-, HER2+/-, TNBC, MSI status, etc.

Competitive Landscape

- Highest number of studies of any indication, investment, and rapidly evolving therapies

Global Disparities in Standard of Care (SoC)

- Varying and multiple lines of prior therapy

Drug Class Nuances

- Targeted therapies: biomarker selection/CDx
- Immuno-oncology: combination and sequencing with CPIs

40+
Breast Cancer Studies

4,300+
Patients Enrolled

350+
Unique Sites

Global Footprint
NA, EU, APAC, LATAM, MENA

What Sets Us Apart

Biotech Mindset Delivered Worldwide

We are purpose built around a biotech mindset that shapes both our partnership philosophy and delivery model, bringing the agility, responsiveness, and focus needed to meet critical oncology development milestones.

Oncology Expertise and Team Continuity

Oncology expertise is embedded across all functions, ensuring studies are led by professionals who understand the complexities of oncology science and trial execution. With an average of 11+ years of oncology experience across key roles and an industry-leading 90%+ retention rate in the oncology business unit, you can expect a seasoned, specialized team supporting your study end to end.

Flexible solutions & best-in-class technologies

Data-centric approach with visual analytics & clinical science

Site relationships with rapid startup

Global footprint: 4,000+ across NA, EU, LATAM, MENA & APAC

Active Next-Gen Oncology Experience

Operating both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge modalities.

Phase



Early Phase · Late Phase · Observational/LTFU

Indication



Solid · Heme

Drug Class



Immuno-Oncology · Other · Targeted Therapy

Worldwide Clinical Trials

Oncology at Worldwide

Worldwide features a dedicated oncology business unit within our full-service global contract research organization. We partner with biopharmaceutical sponsors to deliver expert-led, globally scalable oncology trials across every phase of development. We help sponsors move fast with confidence and scale without disruption.

Contact us to learn how we can support your oncology program from FIH through registration.